Successful recovery from COVID‐19 in three kidney transplant recipients who received convalescent plasma therapy

Abstract

Novel coronavirus disease 2019 (COVID‐19) is a highly infectious, rapidly spreading viral disease that typically presents with greater severity in patients with underlying medical conditions or those who are immunosuppressed. We present a novel case series of three kidney transplant recipients with COVID‐19 who recovered after receiving COVID‐19 convalescent plasma (CCP) therapy. Physicians should be aware of this potentially useful treatment option. Larger clinical registries and randomized clinical trials should be conducted to further explore the clinical and allograft outcomes associated with CCP use in this population.

Convalescent plasma may be a possible treatment for COVID-19: A systematic review

“…Following removing duplicates and screening of titles and abstracts, we evaluated 153 articles in full text. Among these, we found 45 relevant articles (4RCTs, 11 controlled NRSIs, 7 non-controlled NRSIs and 23 case reports) [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] . Extracted details are presented in Table 1 (RCTs, controlled NRSIs, and non-controlled NRSIs) and table 2 (case report(series)).…”

“… No AEs Karataş A et al [58] Turkey Case report 61y/M – 13.3 (≥1.1 positive) – Mixed cellularity classical Hodgkin lymphoma, autologous stem cell transplantation (ASCT, 6 months ago) After the CPT, his fever resolved after 3 days.He was discharged from the hospital on the 78th day of hospitalization. No AEs Naeem S et al [59] USA Case series(n = 3) 65y/F;35y/F;36y/F Case1: 1 unit case2: 2 units case3: 3 unit Case1:antibody Levels in plasma (index):8.68. case2:antibody index:5.70,8.15 case3:antibody index:5.67. – 3 kidney transplant (KT) recipients They all successful recovery from COVID-19.…”

“…Çınar et al reported an immunocompromised patient due to myelodysplastic syndrome, and attacked by SARS-CoV-2 leading to COVID-19 syndrome, which was successfully managed via the administration of double CP transfusion [50] . Naeem S et al and Jiang J et al reported 4 cases of renal transplantation patients undergoing immunotherapy, two of them were 65 and 70 years old, they were discharged and the use of plasma was helpful for SARS-CoV-2 clearance and her recovery [59] , [63] . Karataş A et al reported a 61-year-old man with a history of mixed cellularity classical Hodgkin lymphoma, autologous stem cell transplantation (6 months ago) [58] .…”

Impact of COVID-19 in solid organ transplant recipients

“…Thus, it seems that sufficient antibody titers may be essential to confer clinical efficacy. Data on the use of CP in SOT recipients are limited to case reports 128,129 . Apart from antibody treatment with CP, several highly active monoclonal antibodies against SARS‐CoV‐2 are currently under evaluation 130,131 .…”

COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review

“…Only a paucity of data has been published on the clinical course of COVID-19 in recipients of solid organ and hematopoietic stem cell transplants [ [45] , [46] , [47] ]. Even fewer data are available on the possible treatments for viral infection is such immunocompromised patients, including the CP use [ [48] , [49] , [50] , [51] , [52] , [53] , [54] ].…”